Biogen Due after five years decreased by 12.1% to $10.90M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Due after five years shows a downward trend with a -37.0% CAGR.
other_available_for_sale_securities_debt_maturities_afte_85bd6a| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $44.20M | $42.80M | $23.80M | $19.30M | $13.90M | $12.90M | $11.30M | $16.00M | $15.10M | $12.40M | $10.90M |
| QoQ Change | — | -3.2% | -44.4% | -18.9% | -28.0% | -7.2% | -12.4% | +41.6% | -5.6% | -17.9% | -12.1% |
| YoY Change | — | — | — | — | -68.6% | -69.9% | -52.5% | -17.1% | +8.6% | — | — |